4 interactions on record
Kinase inhibitors: fostamatinib ↑ R406 (active metabolite of fostamatinib) When coadministering fostamatinib with REYATAZ (with or without ritonavir), monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required.
Source: FDA drug label - atazanavir
Kinase Inhibitors: fostamatinib (also see anticancer agents above ) ↑ fostamatinib metabolite R406 Monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required.
Source: FDA drug label - ritonavir
Fostamatinib Clinical Impact: Fostamatinib increased rosuvastatin exposure more than 2.0-fold. Intervention: In patients taking fostamatinib, do not exceed a dose of rosuvastatin tablets 20 mg once daily.
Source: FDA drug label - rosuvastatin
Fostamatinib Clinical Impact: Fostamatinib increased rosuvastatin exposure more than 2.0-fold. Intervention: In patients taking fostamatinib, do not exceed a dose of rosuvastatin 20 mg once daily.
Source: FDA drug label - rosuvastatin calcium